Monday, 10 April 2017

Hot and Cold Therapy Packs Market - Latest Trends & Insights 2024

Hot and cold therapies are considered one of the easiest, effective, and least expensive treatment to relieve pain and swelling in different parts of the body. These are rational, passive, non-invasive forms of therapy to manage pain. Heat therapy leads to vasodilation, which in turn increases the blood flow in the affected tissues. The rise in blood flow in the target area provides required oxygen and other nutrients, thus accelerating the healing process, while the heat reduces muscle spasm and relaxes stretched muscles leading to pain relief. Heat or thermotherapy is generally used to treat chronic pain such as low back pain, spinal, neck pain, neuropathic pain, and other muscular spasms. Cold therapy or cryotherapy calms down damaged tissues, causes vasoconstriction, which reduces blood circulation and also numbs the nerves decreasing inflammation, pain, and muscle spasm. Cold or cryotherapy is generally used to treat acute pain caused due to injuries such as runner’s knee and freshly pulled muscle.
The global hot and cold therapy packs market is anticipated to be driven by a number of factors such as steep growth in chronic musculoskeletal disorders, increase in global trauma and accident cases, and rise in inclination for non-invasive pain management approaches. Increase in the geriatric population vulnerable to chronic illnesses is also escalating demand for hot and cold therapy packs globally. A report published by the Population Division of the Department of Economic and Social Affairs of the United Nations (UN) in 2013 stated that the number of elderly persons (aged 60 years and above) is estimated to more than double, from 841 million in 2013 to over 2 billion in 2050. In addition, growing stress and unhealthy lifestyles leading to increase in number of patients with neck, back, shoulder, and spinal problems is expected to drive the market. Furthermore, increasing research and development activities by key players to develop new products is likely to boost market growth.
In terms of product, the hot and cold therapy packs market can be divided into dry and moist hot and cold packs or compresses, gel packs, and instant electric hot/cold packs. These are used to manage various conditions including back/spinal problems, neck problems, joint problems, arthritis, neuropathic pain, and surgery. Increasing incidence of lifestyle related disorders is one of the major drivers of the hot and cold therapy packs market. Moreover, increasing inclination toward home care products and growing online marketing of such products is expected to boost the market during the forecast period. Advancements in product technology such as cold/hot wrap fused with knee braces or back support belts are also expected to increase demand in the near future.
Geographically, the hot and cold therapy packs market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America dominates the market due to large pool of patients with musculoskeletal disorders in the region. According to the Centers for Disease Control and Prevention (CDC), over 53 million people in the U.S. are currently affected by arthritis. It is a primary cause of disability in the country and affects more than 1 in 5 people, making it one of the most common chronic conditions in the nation. Additionally, launch of new and advanced products by key players coupled with growing online promotion and sales of these products by customers is expected to drive the market. Developing nations in Asia Pacific are expected to witness the fastest growth during the forecast period. Rising patient pool, growing public awareness about home care, and increasing affordability are the major drivers of the market in these regions.
Key players in the hot and cold therapy packs market include 3M Company, Breg, Inc., Cardinal Health, Inc., Carex Health Brands, Halyard Health, Medline Industries, Inc., Medtronic plc, and Pfizer, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Wednesday, 5 April 2017

Emerging Opportunities in Cell Dissociation Reagents Market

A new market research report by Transparency Market Research presents a detailed overview of the cell dissociation reagents market. The report is titled, “Cell Dissociation Reagents Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024”. The research study provides a comprehensive analysis of the current market status, key industry dynamics, emerging trends, offerings of key providers, market share and size of key major segments, and regulatory landscape in major regions.
The report takes a closer look at the recent technological advancements in non-enzymatic cell dissociation. In addition, prominent research activities in vitro cell culture expected to impact the competitive dynamics are covered in the research analysis. Recent developments in optimized dissociation protocol for human stem cells are highlighted and the factors boosting the use of innovative solutions among various end users are analyzed.
The cell dissociation reagents market is primarily driven by constant technological advances in non-enzymatic cell dissociation techniques and advancements in cell detachment reagent solutions based on non-mammalian and non-bacterial origin. In addition, developments in chelators to reduce neutralization steps and significantly lower enzyme autodegradation for a superior detachment yield are expected to propel the market along the forecast period. Furthermore, the development of advanced cell dissociation products that help researchers meet the demand for gentle and effective detachment for adherent cells is expected to create promising opportunities for market players.
A key trend in the cell dissociation reagents market is the use of recombinant cell dissociation solutions that are not sourced from mammals and thus possess high cell viability and plating efficiency. These reagents find extensive applications in detaching primary fibroblasts, tumor cell lines endothelial cells, neurons, and insect cells as they do not affect functional quality of cell membranes and proteins
However, issues with sterility maintenance, inadequacy of use of some reagents in in vivo diagnostics, occurrences of high decontamination with bacteria, and shorter expiry periods of reagents are the factors likely to impede the growth of the market to an extent. On the other hand, technological advances in developing detachment solutions have led to increased quality control to confirm homogeneity and reliability to provide maximum yield during cell passaging.
Fill the form for an exclusive sample of this report:http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20846
The Asia Pacific market is expected to rise at a steady pace fuelled by burgeoning biotechnology companies due to cost-effective manufacturing of cell dissociation reagents and a large presence of specialty research institutes in various emerging nations in the region. North America is poised to offer enormous opportunities for market players. The impressive growth is attributed to soaring R&D investments, increased adoption of high-performing products and a rise in demand for reliable dissociation reagents for adherent cell culture from several research institutes.
Major companies operating in this market include GE Healthcare, Thermo Fisher Scientific Inc., Sigma-Aldrich Co. LLC., Atlanta Biologicals, Inc., HiMedia Laboratories, Irvine Scientific, Gemini Bio-Products, EuroClone S.p.A., Cyagen Biosciences, Inc., PromoCell GmbH, and STEMCELL Technologies, Inc.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Behavioral Therapy Market - Recommendations for 2016; Emerging Trends and New Technologies Research 2016 - 2023

The report titled, “Behavioral Therapy Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016-2023” by Transparency Market Research sheds light on the key trends, growth opportunities, catalysts, and deterrents of the market, along with key figures, charts, and relevant statistical data.
Behavioral therapy is an umbrella term for the various types of therapies aimed at treating mental disorders. Behavioral therapy lays emphasis on creating consciousness in the mind of an individual about how changes in his/her behavior can bring about changes in feelings. The therapy focuses on the eradication of maladaptive and unwanted behavior via engagement in positive reinforcing activities.
As the incidence of behavioral issues and mental health conditions such as anxiety, depression, phobias, addictions, and obsessive-compulsive disorder (OCD) augments across the world, the global market for behavioral therapy is gaining significant impetus. Depression has surfaced as a key culprit necessitating the adoption of behavioral therapy. The changing work culture over the world has been triggering stress, anxiety, and depression. According to the findings of the U.S. National Institute of Mental Health, anxiety disorders form the most common type of mental illness in the U.S., affecting around 18% of the population or 40 million adults aged 18 and older.
These disorders not only affect the mental health of an individual, but also lead to physical health conditions such as irritable bowel syndrome (IBS), chronic pain, eating disorders, sleep disorders, fibromyalgia, bipolar disorder, headaches, and substance abuse, to name a few. Therefore, the co-occurrence of these conditions will promote more demand for behavioral therapy over the globe.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11792
On the other hand, lower degree of awareness about mental health, the prevalence of social taboos pertaining to mental health conditions, and high costs of behavioral therapies might restrict market growth. However, significant opportunities are likely to surface as the popularity of dialectical behavior therapy rises. Research reveals that the sets of behavioral skills such as distress tolerance, emotional regulation, mindfulness, and interpersonal effectiveness developed via dialectical therapy can help fight substance dependence, eating disorders, and post-traumatic stress disorder (PTSD).
Based on geography, the global market for behavioral therapy has been segmented into Western Europe, Eastern Europe, Latin America, North America, Japan, the Middle East and Africa, and Asia Pacific. North America and Europe appear to be dominating the global scenario, with countries such as the U.S., the U.K., and Germany driving the growth of the market.
The rising geriatric population in Asian countries is a prominent catalyst of the behavioral therapy market in Asia Pacific. The growing awareness about mental health, increasing availability of psychiatric treatments, and rising disposable incomes of the middle class are also accelerating the expansion of the market.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453

Growing Trends in Neuro Critical Care Market

The branch of medicines concerned with life threatening illnesses or injuries of brain is called as Neuro critical care or intensive care. The head or physical trauma of brain are called as traumatic brain injury (TBI). The traumatic brain injury are occurred when there is injury in brain. The brain injury can cause internal damage to the brain parts or skull fracture. Trauma center are intensive care unit or neuro critical care (ICU or CCU) which are medically equipped hospitals or private neuro centers where a neuro specialized health professionals treat complications of infection, accidents, surgery and severe other conditions.
Neuro critical care (NCC) has developed as an individual medical specialty that links neurosurgery, neurology, and critical care medicine for treatment and management of complex severe life threatening neurological complications. The neurological impediments such as subarachnoid hemorrhage, ischemic stroke, intracerebral hemorrhage, aneurysmal, status epilepticus, traumatic spine and brain injuries, and other neurological disorders with multiple-organ failure. The neuro critical care has moved from primary care to the restoration of neurological emergency cases like traumatic subarachnoid hemorrhage, brain injury that are still remain a clinical challenge. About 1.7 million persons sustain a traumatic brain injury every year, by Centers for Disease Control and Prevention (CDC).Among them, about120,000 people have long-standing, substantial loss of function.
The neuro critical care market is segmented as based type of equipment, by Indication and by end user. By equipment type the neuro critical care market is segmented as two main types, diagnostics and monitoring. By diagnostics, the neuro critical care market is further segmented as, Computed Tomography (CAT scan), Magnetic Resonance Imaging (MRI) and Electroencephalography (EEG). The Computed Tomography also called as CT scan uses a computer system to give a detailed picture of brain tissue to determine the location of injury of brain. For more in depth of brain imaging, magnetic resonance imaging is used and it provides three dimensional picture of brain. By monitoring equipment the neuro critical market is segmented as CNS Monitor, CNS Device Interfaces, CNS Advanced ICU Amplifier, CNS Video Camera, CNS Reader, ventilators, and other accessories including Endotracheal tube, Foley catheter, Infusion pumps, Feeding tube, etc. The equipment required for neuro critical care consist of emergency and life support devices, pain management devise, patient monitoring devices etc. to monitor the oxygen saturation in blood, pulse oximeters are used, acute care physiologic monitoring systems to constantly measure vital signs, for continuous monitoring of breathing apnea monitors are used. By Indication, the neuro critical care market is segmented as, Subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, ischemic stroke, spinal cord injury, infections of the brain and spinal cord, neuromuscular disorders, status epilepticus and brain tumors. The rising incidences of stroke and head trauma will boost the growth of market. The increasing advances in neurosurgical techniques owing to rising need for neuro critical care will boost the growth of market over estimated period. By end user the neuro critical care market is segmented as hospital, emergency centers, and specialty clinics. The hospital segment governs the major share of neuro critical care market. In each hospital, atleast one critical care unit is required. The specialty clinics, comprises neuro specialized hospitals or clinics. Specialty clinics is the fast growing segment over forecast period, owing to increasing number of patient preferring specialty clinics for more patient care is provided over there and availability of more number of critical care units.
By geography the neuro critical care market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. The North America will govern the major market of neuro critical care owing to increasing incidences stroke cases in the region. Asia Pacific is most progressive region for neuro critical care market due to increasing accidental cases in the region.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22184
The major players for the market for neuro critical care are Abbott, Teleflex Incorporated, Aspect Medical Systems, Inc., CardioDynamics International Corporation, Medtronic, General Electric Company, Edwards Lifesciences Corporation, Integra LifeSciences Corporation., Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA and Terumo Medical Corporation, among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453

Tuesday, 4 April 2017

Gastrointestinal Drugs Market Segment Forecast up to 2024

The global gastrointestinal drugs market is extremely consolidated, with the top three companies accounting for approximately 61.0% of the market in 2016, finds Transparency Market Research (TMR). These leading players are Takeda Pharmaceutical, Valeant Pharmaceuticals Inc., and Janssen Biotech Inc. The current marketplace is moderately competitive; however in the coming years, with continuous technological advances in diagnostics, the market is expected to witness intense competition among players.
The global market for gastrointestinal drugs was valued at US$45.5 bn in 2015. Expanding at 4.90% CAGR between the period 2016 and 2024, the global market is estimated to reach a valuation of US$61.1 bn by the end of 2024.
Acid Neutralizers Expected to Gain Widespread Popularity in Forthcoming Years
Based on geography, the major regional markets for gastrointestinal drugs are Europe, North America, Asia Pacific, the Middle East & Africa (MEA), and Latin America. Of these, North America dominated the global market with an estimated share of 41.0% in 2016. The substantial growth in the market is attributed to the presence of a favorable reimbursement structure regarding the treatment of chronic gastrointestinal diseases. In addition, a rising geriatric population vulnerable to chronic gastrointestinal disorders is expected to boost the regional market.
The major classes of gastrointestinal drugs are acid neutralizers, antidiarrheal and laxatives, antiemetic and antinauseants, anti-inflammatory drugs, and biologics. Among these drug classes, acid neutralizers are poised to witness substantial demand from patients worldwide. The market for the drug class is expected to witness impressive growth in the coming years due to the increasing prevalence of gastroesophageal reflux disease (GERD) across the globe. The medications for GERDs usually contain antacid as one of the components. Antacids are increasingly preferred as cost-effective medications to reduce gastric irritation.
Rising Prevalence of Gastrointestinal Diseases to Bolster Uptake
The global market for gastrointestinal drugs is mainly driven by the rising prevalence of gastrointestinal diseases across demographics. Coupled with this, the increasing level of awareness related to the availability of cost-effective medications and treatments has spurred the demand for gastrointestinal drugs. In addition, soaring investment in R&D activities related to treatment of various gastrointestinal disorders is expected to propel the market over the forecast period.
However, the growing prevalence of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) in various regions, particularly Asia Pacific, has posed a clinical challenge in finding permanent treatments. These gastrointestinal disorders are characterized by unknown etiology and disease mechanisms, which makes the treatment with drugs difficult. This is expected to hinder the growth of the market to an extent. Nevertheless, continual technological advancements in treatment therapies are anticipated to open up promising opportunities for market players, positively impacting the market.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Kaposi Sarcoma Market Segment Forecast up to 2024

Kaposi Sarcoma Market: Snapshot
Kaposi sarcoma (KS) refers to a type of cancer that develops from the cells lining blood vessels or lymph nodes. The cancer usually appears as tumors on mucosal surfaces or on the skin, but can also develop in body parts such as the digestive tract, or the lungs. The abnormal KS cells cause brown, purple, or red blotches on the skin, called lesions.
The global Kaposi sarcoma market features a rising number of regional vendors commanding prominent shares in their respective regional territories. Owing to the looming patent expiries of several blockbuster drugs, the market is expected to witness the entry of several new companies producing generics. The situation also presents immense growth opportunities for leading companies with new drug formulations in the next few years.
Transparency Market Research states that the global Kaposi sarcoma market will exhibit a modest 2.2% CAGR over the period between 2016 and 2024, rising from a valuation of US$118.5 mn in 2015 to US$143.2 mn by 2024.
Chemotherapy Continues to Remain Most Preferred Course of Treatment despite High Cost
The key treatment methods for Kaposi sarcoma include immunotherapy, chemotherapy, and antiretroviral therapy. Of these, the segment of antiretroviral therapy emerged at the leading segment owing to the high incidence rate of AIDS-related Kaposi sarcoma. The segment will continue to grow at an encouraging pace in the next few years as well.
Over the report’s forecast period, however, the segment of chemotherapy is expected to exhibit growth at the most promising pace, chiefly owing to the high treatment cost and the high preference given to the treatment method by immunocompetent patients. Some of the most popular chemotherapy drugs in the market are vincristine, docetaxel, paclitaxel, bleomicin, daunorubicin, and liposomal doxorubicin. Although the high preference to this treatment method, its high cost could emerge as a key deterrent to patient population across some regions, especially across developing and less developed economies across Asia Pacific and Africa, limiting its growth prospects.
North America to Retain Dominance in Global Market despite a Low Rate of Prevalence of Kaposi Sarcoma
From a geographical standpoint, North America is presently the leading contributor of revenue to the global Kaposi sarcoma market. The region holds a leading position in the global market owing to the presence of some of the world’s leading vendors in the field and the rising costs of drugs. The North America market for Kaposi sarcoma also benefits from the high rate of diagnosis of the condition and the easy availability of drugs. The region features a low incidence rate of the disease but has been witnessing a shortage in supply of drugs required for its treatment, leading to a wide demand-supply gap and subsequently significant scope of growth.
Over the report’s forecast period, the market is expected to witness the most promising rate of growth in the Middle East and Africa region. The region is expected to lead to the heightened demand for Kaposi sarcoma drugs owing to the high rate of incidence of the disease. The high rate of prevalence of HIV/AIDS is and thus the increased prevalence of AIDS induced Kaposi sarcoma in Eastern Africa is also a key driving factor, along with the fact that awareness among people is low.
Some of the leading players operating in the immensely consolidated vendor landscape of the global Kaposi sarcoma market are Johnson & Johnson, Merck & Co., Inc., Bristol Myers Squibb, Hoffman-La Roche, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Eli Lilly and Co.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

North America Oxygen Therapy Devices Market Segment Forecast up to 2023

According to a new market report published by Transparency Market Research “Oxygen Therapy Devices Market - North America Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” the North America oxygen therapy devices market was valued at US$ 1.0 Bn in 2014 and is expected to grow at a CAGR of 5.5% from 2015 to 2023, to reach an estimated value of US$ 1.58 Bn in 2023.
 Oxygen therapy is a form of respiratory care that involves administration of supplemental oxygen in order to prevent any damage to tissue cells as a result of hypoxemia. The prime purpose of oxygen therapy is to increase oxygen saturation levels in the damaged tissues. Oxygen therapy results in reduction in shortness of breath, lesser strain on the heart and better quality of life. Increasing incidences of various respiratory illnesses and growing need for better disease management is driving the growth of the global oxygen therapy devices market. Due to its wide application in the treatment of a number of diseases including chronic obstructive pulmonary disease, asthma, pneumonia, obstructive sleep apnea, respiratory distress syndrome and cystic fibrosis, the oxygen therapy devices market is estimated to propel during the forecast period of 2015 to 2023.
 Geographically, the North America oxygen therapy devices market is segmented into the U.S. and Canada. The U.S. held the largest market in terms of revenue in 2014 and is expected to dominate the position throughout the forecast period. Major factors attributed to the dominance of the U.S. are increasing prevalence of chronic obstructive pulmonary disease (COPD) among the regional population, growing health care awareness regarding the availability of treatment for a wide range of chronic respiratory diseases and demand for technologically advanced devices. According to the American Lung Association, COPD is the third leading cause of death in the U.S., with 11 million people diagnosed with COPD and another 24 million people are estimated to be affected from the disease but are unaware of their situation in 2013. Moreover, increasing government initiatives has also fueled the growth of the market. For instance, the National Asthma Control Initiative (NACI), a program of the National Asthma Education and Prevention Program (NAEPP) in the U.S., aims to produce high-impact solutions and meaningful change in asthma control. The NACI is an action-oriented initiative to engage health care professionals, patients, professional associations, and other stakeholders in order to implement innovative and strategic interventions, thereby reducing asthma disparities. Similarly, the U.S.-based National Prevention Strategy for Tobacco Free Living leads initiatives to improve health through prevention by expanding clinical and community-based preventive services.
 The oxygen therapy devices market in Canada is witnessing significant growth. Factors attributed to the growth of the market are rising geriatric population, high adoption of premium priced devices and rising prevalence of respiratory diseases. According to the Statistics Canada, 16.1% or approximately 5,780,900 people in Canada are 65 years and older who are more likely to suffer from the respiratory disease. Moreover, demand for oxygen therapy products is largely driven by the increasing prevalence of COPD, which affects more than 714,000 people in Canada and is currently the 4th leading cause of death. It is estimated to be the third largest cause of death by 2020.
 The market exhibits intense competition among existing players, as currently the market for oxygen therapy devices is highly consolidated, comprising a few established companies. Some of the top players operating in the North America oxygen therapy devices market are CareFusion Corporation, DeVilbiss Healthcare, LLC, Fisher & Paykel Healthcare Limited, MAQUET Holding B.V. & Co. KG, Smiths Medical, Teleflex Incorporated, Invacare Corporation, Philips Respironics, Inc., and AirSep Corporation.
 The North America oxygen therapy devices market is segmented as follows:
 North America Oxygen Therapy Devices Market, by Product Type 
  • Oxygen Source Equipment
    • Oxygen Cylinders
    • Oxygen Concentrators
    • Liquid Oxygen Devices
  • Oxygen Delivery Devices
    • Simple Oxygen Mask
    • Nasal Cannula
    • Venturi Mask
    • Non-rebreather Mask
    • Bag Valve mask
    • CPAP Mask 
North America Oxygen Therapy Devices Market, by Applications 
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Obstructive Sleep Apnea
  • Respiratory Distress Syndrome (RDS)
  • Cystic Fibrosis
  • Pneumonia
 Oxygen Therapy Devices Market, by Geography 
  • United States
  • Canada
 Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453